nodes	percent_of_prediction	percent_of_DWPC	metapath
Lurasidone—CYP3A4—Temozolomide—skin cancer	0.151	0.292	CbGbCtD
Lurasidone—CYP3A4—Imiquimod—skin cancer	0.151	0.292	CbGbCtD
Lurasidone—CYP3A4—Vismodegib—skin cancer	0.105	0.202	CbGbCtD
Lurasidone—CYP3A4—Vemurafenib—skin cancer	0.0828	0.16	CbGbCtD
Lurasidone—CYP3A4—Docetaxel—skin cancer	0.0284	0.0548	CbGbCtD
Lurasidone—HTR2A—hindlimb—skin cancer	0.00476	0.0762	CbGeAlD
Lurasidone—HTR7—nerve—skin cancer	0.00464	0.0743	CbGeAlD
Lurasidone—DRD2—nerve—skin cancer	0.00438	0.0702	CbGeAlD
Lurasidone—HTR2A—appendage—skin cancer	0.00408	0.0654	CbGeAlD
Lurasidone—HTR7—endothelium—skin cancer	0.00395	0.0633	CbGeAlD
Lurasidone—HTR7—blood vessel—skin cancer	0.00364	0.0583	CbGeAlD
Lurasidone—HTR2A—nerve—skin cancer	0.00289	0.0463	CbGeAlD
Lurasidone—HTR7—neck—skin cancer	0.00261	0.0417	CbGeAlD
Lurasidone—HTR2A—endothelium—skin cancer	0.00246	0.0395	CbGeAlD
Lurasidone—ADRA2C—nipple—skin cancer	0.00242	0.0388	CbGeAlD
Lurasidone—HTR2A—blood vessel—skin cancer	0.00227	0.0364	CbGeAlD
Lurasidone—ADRA2A—nipple—skin cancer	0.00193	0.0309	CbGeAlD
Lurasidone—HTR7—connective tissue—skin cancer	0.00187	0.0299	CbGeAlD
Lurasidone—HTR7—epithelium—skin cancer	0.00177	0.0284	CbGeAlD
Lurasidone—Angiopathy—Imiquimod—skin cancer	0.00171	0.00408	CcSEcCtD
Lurasidone—Amenorrhoea—Docetaxel—skin cancer	0.0017	0.00406	CcSEcCtD
Lurasidone—Arrhythmia—Imiquimod—skin cancer	0.00168	0.00402	CcSEcCtD
Lurasidone—Mental disorder—Imiquimod—skin cancer	0.00165	0.00394	CcSEcCtD
Lurasidone—Malnutrition—Imiquimod—skin cancer	0.00164	0.00391	CcSEcCtD
Lurasidone—Myalgia—Vemurafenib—skin cancer	0.00164	0.00391	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.00163	0.00388	CcSEcCtD
Lurasidone—HTR2A—neck—skin cancer	0.00162	0.026	CbGeAlD
Lurasidone—Vomiting—Vismodegib—skin cancer	0.00162	0.00385	CcSEcCtD
Lurasidone—Rash—Vismodegib—skin cancer	0.0016	0.00382	CcSEcCtD
Lurasidone—Dermatitis—Vismodegib—skin cancer	0.0016	0.00382	CcSEcCtD
Lurasidone—Back pain—Imiquimod—skin cancer	0.00159	0.00379	CcSEcCtD
Lurasidone—Dysphagia—Dactinomycin—skin cancer	0.00156	0.00372	CcSEcCtD
Lurasidone—Infection—Vemurafenib—skin cancer	0.00156	0.00372	CcSEcCtD
Lurasidone—Nervous system disorder—Vemurafenib—skin cancer	0.00154	0.00367	CcSEcCtD
Lurasidone—Lethargy—Fluorouracil—skin cancer	0.00154	0.00366	CcSEcCtD
Lurasidone—Skin disorder—Vemurafenib—skin cancer	0.00153	0.00364	CcSEcCtD
Lurasidone—Nausea—Vismodegib—skin cancer	0.00151	0.0036	CcSEcCtD
Lurasidone—Agitation—Imiquimod—skin cancer	0.00151	0.0036	CcSEcCtD
Lurasidone—Osteoarthritis—Fluorouracil—skin cancer	0.0015	0.00359	CcSEcCtD
Lurasidone—Angioedema—Imiquimod—skin cancer	0.0015	0.00358	CcSEcCtD
Lurasidone—Pulmonary embolism—Docetaxel—skin cancer	0.0015	0.00357	CcSEcCtD
Lurasidone—Blood pressure increased—Docetaxel—skin cancer	0.0015	0.00357	CcSEcCtD
Lurasidone—Malaise—Imiquimod—skin cancer	0.00148	0.00353	CcSEcCtD
Lurasidone—Breast disorder—Temozolomide—skin cancer	0.00148	0.00352	CcSEcCtD
Lurasidone—Syncope—Imiquimod—skin cancer	0.00147	0.00351	CcSEcCtD
Lurasidone—Hypotension—Vemurafenib—skin cancer	0.00147	0.0035	CcSEcCtD
Lurasidone—Neutropenia—Dactinomycin—skin cancer	0.00146	0.00348	CcSEcCtD
Lurasidone—Loss of consciousness—Imiquimod—skin cancer	0.00144	0.00344	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Temozolomide—skin cancer	0.00144	0.00343	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00143	0.00341	CcSEcCtD
Lurasidone—Convulsion—Imiquimod—skin cancer	0.00142	0.00339	CcSEcCtD
Lurasidone—Hypertension—Imiquimod—skin cancer	0.00142	0.00338	CcSEcCtD
Lurasidone—ADRA2C—mammalian vulva—skin cancer	0.00141	0.0226	CbGeAlD
Lurasidone—Dysphagia—Temozolomide—skin cancer	0.00141	0.00337	CcSEcCtD
Lurasidone—Myalgia—Imiquimod—skin cancer	0.0014	0.00333	CcSEcCtD
Lurasidone—Anxiety—Imiquimod—skin cancer	0.00139	0.00332	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.00139	0.00331	CcSEcCtD
Lurasidone—ADRA2A—connective tissue—skin cancer	0.00137	0.0219	CbGeAlD
Lurasidone—Dry mouth—Imiquimod—skin cancer	0.00137	0.00326	CcSEcCtD
Lurasidone—Decreased appetite—Vemurafenib—skin cancer	0.00137	0.00326	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00136	0.00323	CcSEcCtD
Lurasidone—Fatigue—Vemurafenib—skin cancer	0.00135	0.00323	CcSEcCtD
Lurasidone—Nasopharyngitis—Fluorouracil—skin cancer	0.00135	0.00321	CcSEcCtD
Lurasidone—Infection—Imiquimod—skin cancer	0.00133	0.00317	CcSEcCtD
Lurasidone—Neutropenia—Temozolomide—skin cancer	0.00132	0.00315	CcSEcCtD
Lurasidone—Dysuria—Temozolomide—skin cancer	0.00132	0.00315	CcSEcCtD
Lurasidone—Shock—Imiquimod—skin cancer	0.00132	0.00314	CcSEcCtD
Lurasidone—HTR7—female reproductive system—skin cancer	0.00132	0.0211	CbGeAlD
Lurasidone—Nervous system disorder—Imiquimod—skin cancer	0.00131	0.00313	CcSEcCtD
Lurasidone—Tachycardia—Imiquimod—skin cancer	0.00131	0.00312	CcSEcCtD
Lurasidone—Skin disorder—Imiquimod—skin cancer	0.0013	0.0031	CcSEcCtD
Lurasidone—Dysphagia—Fluorouracil—skin cancer	0.0013	0.0031	CcSEcCtD
Lurasidone—Erectile dysfunction—Temozolomide—skin cancer	0.0013	0.0031	CcSEcCtD
Lurasidone—Agranulocytosis—Dactinomycin—skin cancer	0.0013	0.0031	CcSEcCtD
Lurasidone—Hyperhidrosis—Imiquimod—skin cancer	0.00129	0.00309	CcSEcCtD
Lurasidone—Eosinophilia—Fluorouracil—skin cancer	0.00129	0.00307	CcSEcCtD
Lurasidone—Weight increased—Temozolomide—skin cancer	0.00128	0.00306	CcSEcCtD
Lurasidone—Hyperglycaemia—Temozolomide—skin cancer	0.00127	0.00304	CcSEcCtD
Lurasidone—Angina pectoris—Fluorouracil—skin cancer	0.00127	0.00302	CcSEcCtD
Lurasidone—Infestation NOS—Temozolomide—skin cancer	0.00126	0.003	CcSEcCtD
Lurasidone—Infestation—Temozolomide—skin cancer	0.00126	0.003	CcSEcCtD
Lurasidone—Urinary tract infection—Temozolomide—skin cancer	0.00122	0.00292	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00122	0.00291	CcSEcCtD
Lurasidone—Insomnia—Imiquimod—skin cancer	0.00121	0.00289	CcSEcCtD
Lurasidone—Dyspnoea—Imiquimod—skin cancer	0.00119	0.00285	CcSEcCtD
Lurasidone—Somnolence—Imiquimod—skin cancer	0.00119	0.00284	CcSEcCtD
Lurasidone—Hepatobiliary disease—Temozolomide—skin cancer	0.00119	0.00284	CcSEcCtD
Lurasidone—Dyspepsia—Imiquimod—skin cancer	0.00118	0.00281	CcSEcCtD
Lurasidone—HTR2A—connective tissue—skin cancer	0.00116	0.0187	CbGeAlD
Lurasidone—Decreased appetite—Imiquimod—skin cancer	0.00116	0.00278	CcSEcCtD
Lurasidone—Hot flush—Docetaxel—skin cancer	0.00116	0.00277	CcSEcCtD
Lurasidone—Infestation NOS—Fluorouracil—skin cancer	0.00116	0.00276	CcSEcCtD
Lurasidone—Infestation—Fluorouracil—skin cancer	0.00116	0.00276	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Imiquimod—skin cancer	0.00116	0.00276	CcSEcCtD
Lurasidone—Fatigue—Imiquimod—skin cancer	0.00115	0.00275	CcSEcCtD
Lurasidone—HTR1A—head—skin cancer	0.00115	0.0184	CbGeAlD
Lurasidone—Menopausal symptoms—Docetaxel—skin cancer	0.00115	0.00274	CcSEcCtD
Lurasidone—ADRA2A—mammalian vulva—skin cancer	0.00113	0.0181	CbGeAlD
Lurasidone—Urinary tract infection—Fluorouracil—skin cancer	0.00113	0.00269	CcSEcCtD
Lurasidone—Asthenia—Vemurafenib—skin cancer	0.00113	0.00269	CcSEcCtD
Lurasidone—Urinary tract disorder—Temozolomide—skin cancer	0.00112	0.00266	CcSEcCtD
Lurasidone—Pruritus—Vemurafenib—skin cancer	0.00111	0.00265	CcSEcCtD
Lurasidone—Connective tissue disorder—Temozolomide—skin cancer	0.00111	0.00265	CcSEcCtD
Lurasidone—Lethargy—Docetaxel—skin cancer	0.00111	0.00264	CcSEcCtD
Lurasidone—Urethral disorder—Temozolomide—skin cancer	0.00111	0.00264	CcSEcCtD
Lurasidone—HTR2A—epithelium—skin cancer	0.00111	0.0177	CbGeAlD
Lurasidone—HTR7—head—skin cancer	0.0011	0.0176	CbGeAlD
Lurasidone—Gastrointestinal pain—Imiquimod—skin cancer	0.0011	0.00261	CcSEcCtD
Lurasidone—Agranulocytosis—Fluorouracil—skin cancer	0.00108	0.00258	CcSEcCtD
Lurasidone—Anaemia—Bleomycin—skin cancer	0.00108	0.00257	CcSEcCtD
Lurasidone—Diarrhoea—Vemurafenib—skin cancer	0.00107	0.00256	CcSEcCtD
Lurasidone—Abdominal pain—Imiquimod—skin cancer	0.00106	0.00252	CcSEcCtD
Lurasidone—Eye disorder—Temozolomide—skin cancer	0.00106	0.00252	CcSEcCtD
Lurasidone—Malaise—Bleomycin—skin cancer	0.00105	0.00251	CcSEcCtD
Lurasidone—Cardiac disorder—Temozolomide—skin cancer	0.00105	0.0025	CcSEcCtD
Lurasidone—Leukopenia—Bleomycin—skin cancer	0.00104	0.00249	CcSEcCtD
Lurasidone—DRD2—head—skin cancer	0.00104	0.0167	CbGeAlD
Lurasidone—Dizziness—Vemurafenib—skin cancer	0.00104	0.00248	CcSEcCtD
Lurasidone—Angiopathy—Temozolomide—skin cancer	0.00102	0.00244	CcSEcCtD
Lurasidone—ADRA2C—head—skin cancer	0.00101	0.0162	CbGeAlD
Lurasidone—Anaemia—Dactinomycin—skin cancer	0.001	0.0024	CcSEcCtD
Lurasidone—Vomiting—Vemurafenib—skin cancer	0.000998	0.00238	CcSEcCtD
Lurasidone—Myalgia—Bleomycin—skin cancer	0.000992	0.00237	CcSEcCtD
Lurasidone—Orthostatic hypotension—Docetaxel—skin cancer	0.000992	0.00237	CcSEcCtD
Lurasidone—Abdominal pain upper—Docetaxel—skin cancer	0.000992	0.00237	CcSEcCtD
Lurasidone—Rash—Vemurafenib—skin cancer	0.00099	0.00236	CcSEcCtD
Lurasidone—Mental disorder—Temozolomide—skin cancer	0.00099	0.00236	CcSEcCtD
Lurasidone—Dermatitis—Vemurafenib—skin cancer	0.000989	0.00236	CcSEcCtD
Lurasidone—Malnutrition—Temozolomide—skin cancer	0.000983	0.00234	CcSEcCtD
Lurasidone—Breast disorder—Docetaxel—skin cancer	0.000981	0.00234	CcSEcCtD
Lurasidone—Malaise—Dactinomycin—skin cancer	0.00098	0.00234	CcSEcCtD
Lurasidone—Leukopenia—Dactinomycin—skin cancer	0.000973	0.00232	CcSEcCtD
Lurasidone—Nasopharyngitis—Docetaxel—skin cancer	0.000971	0.00232	CcSEcCtD
Lurasidone—ADRA2A—female reproductive system—skin cancer	0.000966	0.0155	CbGeAlD
Lurasidone—Asthenia—Imiquimod—skin cancer	0.000961	0.00229	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000958	0.00228	CcSEcCtD
Lurasidone—Back pain—Temozolomide—skin cancer	0.000951	0.00227	CcSEcCtD
Lurasidone—Pruritus—Imiquimod—skin cancer	0.000947	0.00226	CcSEcCtD
Lurasidone—Infection—Bleomycin—skin cancer	0.000945	0.00225	CcSEcCtD
Lurasidone—Dysphagia—Docetaxel—skin cancer	0.000938	0.00224	CcSEcCtD
Lurasidone—Nausea—Vemurafenib—skin cancer	0.000933	0.00222	CcSEcCtD
Lurasidone—Arrhythmia—Fluorouracil—skin cancer	0.00093	0.00222	CcSEcCtD
Lurasidone—Vision blurred—Temozolomide—skin cancer	0.000927	0.00221	CcSEcCtD
Lurasidone—Myalgia—Dactinomycin—skin cancer	0.000926	0.00221	CcSEcCtD
Lurasidone—Tremor—Temozolomide—skin cancer	0.000921	0.0022	CcSEcCtD
Lurasidone—Diarrhoea—Imiquimod—skin cancer	0.000916	0.00219	CcSEcCtD
Lurasidone—Angina pectoris—Docetaxel—skin cancer	0.000914	0.00218	CcSEcCtD
Lurasidone—Anaemia—Temozolomide—skin cancer	0.000909	0.00217	CcSEcCtD
Lurasidone—Agitation—Temozolomide—skin cancer	0.000904	0.00215	CcSEcCtD
Lurasidone—Angioedema—Temozolomide—skin cancer	0.000899	0.00214	CcSEcCtD
Lurasidone—Hypotension—Bleomycin—skin cancer	0.000889	0.00212	CcSEcCtD
Lurasidone—Malaise—Temozolomide—skin cancer	0.000887	0.00211	CcSEcCtD
Lurasidone—Dizziness—Imiquimod—skin cancer	0.000886	0.00211	CcSEcCtD
Lurasidone—Vertigo—Temozolomide—skin cancer	0.000883	0.00211	CcSEcCtD
Lurasidone—Infection—Dactinomycin—skin cancer	0.000881	0.0021	CcSEcCtD
Lurasidone—Leukopenia—Temozolomide—skin cancer	0.00088	0.0021	CcSEcCtD
Lurasidone—Neutropenia—Docetaxel—skin cancer	0.000878	0.00209	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000867	0.00207	CcSEcCtD
Lurasidone—Weight increased—Docetaxel—skin cancer	0.000854	0.00204	CcSEcCtD
Lurasidone—Vision blurred—Fluorouracil—skin cancer	0.000854	0.00204	CcSEcCtD
Lurasidone—Convulsion—Temozolomide—skin cancer	0.000852	0.00203	CcSEcCtD
Lurasidone—Vomiting—Imiquimod—skin cancer	0.000851	0.00203	CcSEcCtD
Lurasidone—Hypertension—Temozolomide—skin cancer	0.000849	0.00202	CcSEcCtD
Lurasidone—Dyspnoea—Bleomycin—skin cancer	0.000848	0.00202	CcSEcCtD
Lurasidone—Rash—Imiquimod—skin cancer	0.000844	0.00201	CcSEcCtD
Lurasidone—Dermatitis—Imiquimod—skin cancer	0.000844	0.00201	CcSEcCtD
Lurasidone—Anaemia—Fluorouracil—skin cancer	0.000837	0.002	CcSEcCtD
Lurasidone—Myalgia—Temozolomide—skin cancer	0.000837	0.002	CcSEcCtD
Lurasidone—Infestation—Docetaxel—skin cancer	0.000837	0.002	CcSEcCtD
Lurasidone—Infestation NOS—Docetaxel—skin cancer	0.000837	0.002	CcSEcCtD
Lurasidone—Anxiety—Temozolomide—skin cancer	0.000834	0.00199	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000831	0.00198	CcSEcCtD
Lurasidone—Decreased appetite—Bleomycin—skin cancer	0.000827	0.00197	CcSEcCtD
Lurasidone—Renal failure—Docetaxel—skin cancer	0.000823	0.00196	CcSEcCtD
Lurasidone—HTR2A—female reproductive system—skin cancer	0.000821	0.0132	CbGeAlD
Lurasidone—Dry mouth—Temozolomide—skin cancer	0.000819	0.00195	CcSEcCtD
Lurasidone—Leukopenia—Fluorouracil—skin cancer	0.000811	0.00193	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000808	0.00193	CcSEcCtD
Lurasidone—ADRA2A—head—skin cancer	0.000807	0.0129	CbGeAlD
Lurasidone—Infection—Temozolomide—skin cancer	0.000797	0.0019	CcSEcCtD
Lurasidone—Nausea—Imiquimod—skin cancer	0.000795	0.0019	CcSEcCtD
Lurasidone—Hepatobiliary disease—Docetaxel—skin cancer	0.000791	0.00189	CcSEcCtD
Lurasidone—Nervous system disorder—Temozolomide—skin cancer	0.000787	0.00188	CcSEcCtD
Lurasidone—Convulsion—Fluorouracil—skin cancer	0.000785	0.00187	CcSEcCtD
Lurasidone—Agranulocytosis—Docetaxel—skin cancer	0.000781	0.00186	CcSEcCtD
Lurasidone—Skin disorder—Temozolomide—skin cancer	0.00078	0.00186	CcSEcCtD
Lurasidone—Hyperhidrosis—Temozolomide—skin cancer	0.000776	0.00185	CcSEcCtD
Lurasidone—Myalgia—Fluorouracil—skin cancer	0.000771	0.00184	CcSEcCtD
Lurasidone—Decreased appetite—Dactinomycin—skin cancer	0.000771	0.00184	CcSEcCtD
Lurasidone—Fatigue—Dactinomycin—skin cancer	0.000765	0.00182	CcSEcCtD
Lurasidone—CYP3A4—female reproductive system—skin cancer	0.00076	0.0122	CbGeAlD
Lurasidone—Urinary tract disorder—Docetaxel—skin cancer	0.000742	0.00177	CcSEcCtD
Lurasidone—Connective tissue disorder—Docetaxel—skin cancer	0.000738	0.00176	CcSEcCtD
Lurasidone—Urethral disorder—Docetaxel—skin cancer	0.000736	0.00176	CcSEcCtD
Lurasidone—Infection—Fluorouracil—skin cancer	0.000735	0.00175	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000731	0.00174	CcSEcCtD
Lurasidone—Insomnia—Temozolomide—skin cancer	0.000726	0.00173	CcSEcCtD
Lurasidone—Gastrointestinal pain—Dactinomycin—skin cancer	0.000726	0.00173	CcSEcCtD
Lurasidone—Nervous system disorder—Fluorouracil—skin cancer	0.000725	0.00173	CcSEcCtD
Lurasidone—Tachycardia—Fluorouracil—skin cancer	0.000722	0.00172	CcSEcCtD
Lurasidone—Dyspnoea—Temozolomide—skin cancer	0.000715	0.00171	CcSEcCtD
Lurasidone—Somnolence—Temozolomide—skin cancer	0.000713	0.0017	CcSEcCtD
Lurasidone—ADRA2C—lymph node—skin cancer	0.000708	0.0113	CbGeAlD
Lurasidone—Dyspepsia—Temozolomide—skin cancer	0.000706	0.00168	CcSEcCtD
Lurasidone—Eye disorder—Docetaxel—skin cancer	0.000702	0.00167	CcSEcCtD
Lurasidone—Abdominal pain—Dactinomycin—skin cancer	0.000701	0.00167	CcSEcCtD
Lurasidone—Decreased appetite—Temozolomide—skin cancer	0.000698	0.00166	CcSEcCtD
Lurasidone—Cardiac disorder—Docetaxel—skin cancer	0.000697	0.00166	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Temozolomide—skin cancer	0.000693	0.00165	CcSEcCtD
Lurasidone—Fatigue—Temozolomide—skin cancer	0.000692	0.00165	CcSEcCtD
Lurasidone—Hypotension—Fluorouracil—skin cancer	0.000691	0.00165	CcSEcCtD
Lurasidone—HTR2A—head—skin cancer	0.000686	0.011	CbGeAlD
Lurasidone—Asthenia—Bleomycin—skin cancer	0.000683	0.00163	CcSEcCtD
Lurasidone—Angiopathy—Docetaxel—skin cancer	0.000682	0.00163	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000674	0.00161	CcSEcCtD
Lurasidone—Pruritus—Bleomycin—skin cancer	0.000673	0.00161	CcSEcCtD
Lurasidone—Arrhythmia—Docetaxel—skin cancer	0.000671	0.0016	CcSEcCtD
Lurasidone—Insomnia—Fluorouracil—skin cancer	0.000669	0.00159	CcSEcCtD
Lurasidone—Dyspnoea—Fluorouracil—skin cancer	0.000659	0.00157	CcSEcCtD
Lurasidone—Mental disorder—Docetaxel—skin cancer	0.000658	0.00157	CcSEcCtD
Lurasidone—Somnolence—Fluorouracil—skin cancer	0.000657	0.00157	CcSEcCtD
Lurasidone—Gastrointestinal pain—Temozolomide—skin cancer	0.000656	0.00156	CcSEcCtD
Lurasidone—Malnutrition—Docetaxel—skin cancer	0.000654	0.00156	CcSEcCtD
Lurasidone—Dyspepsia—Fluorouracil—skin cancer	0.000651	0.00155	CcSEcCtD
Lurasidone—Decreased appetite—Fluorouracil—skin cancer	0.000643	0.00153	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000638	0.00152	CcSEcCtD
Lurasidone—Asthenia—Dactinomycin—skin cancer	0.000637	0.00152	CcSEcCtD
Lurasidone—Abdominal pain—Temozolomide—skin cancer	0.000634	0.00151	CcSEcCtD
Lurasidone—Back pain—Docetaxel—skin cancer	0.000633	0.00151	CcSEcCtD
Lurasidone—Muscle spasms—Docetaxel—skin cancer	0.000629	0.0015	CcSEcCtD
Lurasidone—Diarrhoea—Dactinomycin—skin cancer	0.000607	0.00145	CcSEcCtD
Lurasidone—Vomiting—Bleomycin—skin cancer	0.000605	0.00144	CcSEcCtD
Lurasidone—Anaemia—Docetaxel—skin cancer	0.000604	0.00144	CcSEcCtD
Lurasidone—Rash—Bleomycin—skin cancer	0.0006	0.00143	CcSEcCtD
Lurasidone—Dermatitis—Bleomycin—skin cancer	0.000599	0.00143	CcSEcCtD
Lurasidone—Syncope—Docetaxel—skin cancer	0.000586	0.0014	CcSEcCtD
Lurasidone—Leukopenia—Docetaxel—skin cancer	0.000585	0.0014	CcSEcCtD
Lurasidone—Asthenia—Temozolomide—skin cancer	0.000576	0.00137	CcSEcCtD
Lurasidone—Loss of consciousness—Docetaxel—skin cancer	0.000575	0.00137	CcSEcCtD
Lurasidone—Pruritus—Temozolomide—skin cancer	0.000568	0.00135	CcSEcCtD
Lurasidone—Convulsion—Docetaxel—skin cancer	0.000567	0.00135	CcSEcCtD
Lurasidone—Nausea—Bleomycin—skin cancer	0.000565	0.00135	CcSEcCtD
Lurasidone—ADRA2A—lymph node—skin cancer	0.000565	0.00905	CbGeAlD
Lurasidone—Hypertension—Docetaxel—skin cancer	0.000565	0.00135	CcSEcCtD
Lurasidone—Vomiting—Dactinomycin—skin cancer	0.000564	0.00135	CcSEcCtD
Lurasidone—Rash—Dactinomycin—skin cancer	0.000559	0.00133	CcSEcCtD
Lurasidone—Myalgia—Docetaxel—skin cancer	0.000557	0.00133	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000553	0.00132	CcSEcCtD
Lurasidone—Diarrhoea—Temozolomide—skin cancer	0.000549	0.00131	CcSEcCtD
Lurasidone—Dry mouth—Docetaxel—skin cancer	0.000544	0.0013	CcSEcCtD
Lurasidone—Dizziness—Temozolomide—skin cancer	0.000531	0.00127	CcSEcCtD
Lurasidone—Infection—Docetaxel—skin cancer	0.00053	0.00126	CcSEcCtD
Lurasidone—Nausea—Dactinomycin—skin cancer	0.000527	0.00126	CcSEcCtD
Lurasidone—Shock—Docetaxel—skin cancer	0.000525	0.00125	CcSEcCtD
Lurasidone—Nervous system disorder—Docetaxel—skin cancer	0.000523	0.00125	CcSEcCtD
Lurasidone—Pruritus—Fluorouracil—skin cancer	0.000523	0.00125	CcSEcCtD
Lurasidone—Tachycardia—Docetaxel—skin cancer	0.000521	0.00124	CcSEcCtD
Lurasidone—Skin disorder—Docetaxel—skin cancer	0.000518	0.00124	CcSEcCtD
Lurasidone—Vomiting—Temozolomide—skin cancer	0.00051	0.00122	CcSEcCtD
Lurasidone—Rash—Temozolomide—skin cancer	0.000506	0.00121	CcSEcCtD
Lurasidone—Diarrhoea—Fluorouracil—skin cancer	0.000506	0.00121	CcSEcCtD
Lurasidone—Dermatitis—Temozolomide—skin cancer	0.000506	0.00121	CcSEcCtD
Lurasidone—Hypotension—Docetaxel—skin cancer	0.000499	0.00119	CcSEcCtD
Lurasidone—Dizziness—Fluorouracil—skin cancer	0.000489	0.00117	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000486	0.00116	CcSEcCtD
Lurasidone—Insomnia—Docetaxel—skin cancer	0.000483	0.00115	CcSEcCtD
Lurasidone—Nausea—Temozolomide—skin cancer	0.000477	0.00114	CcSEcCtD
Lurasidone—Dyspnoea—Docetaxel—skin cancer	0.000476	0.00113	CcSEcCtD
Lurasidone—Somnolence—Docetaxel—skin cancer	0.000474	0.00113	CcSEcCtD
Lurasidone—Vomiting—Fluorouracil—skin cancer	0.00047	0.00112	CcSEcCtD
Lurasidone—Dyspepsia—Docetaxel—skin cancer	0.00047	0.00112	CcSEcCtD
Lurasidone—Rash—Fluorouracil—skin cancer	0.000466	0.00111	CcSEcCtD
Lurasidone—Dermatitis—Fluorouracil—skin cancer	0.000466	0.00111	CcSEcCtD
Lurasidone—Decreased appetite—Docetaxel—skin cancer	0.000464	0.00111	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Docetaxel—skin cancer	0.000461	0.0011	CcSEcCtD
Lurasidone—Fatigue—Docetaxel—skin cancer	0.00046	0.0011	CcSEcCtD
Lurasidone—Nausea—Fluorouracil—skin cancer	0.000439	0.00105	CcSEcCtD
Lurasidone—Gastrointestinal pain—Docetaxel—skin cancer	0.000436	0.00104	CcSEcCtD
Lurasidone—Abdominal pain—Docetaxel—skin cancer	0.000422	0.00101	CcSEcCtD
Lurasidone—Asthenia—Docetaxel—skin cancer	0.000383	0.000913	CcSEcCtD
Lurasidone—Pruritus—Docetaxel—skin cancer	0.000378	0.0009	CcSEcCtD
Lurasidone—Diarrhoea—Docetaxel—skin cancer	0.000365	0.000871	CcSEcCtD
Lurasidone—Dizziness—Docetaxel—skin cancer	0.000353	0.000842	CcSEcCtD
Lurasidone—Vomiting—Docetaxel—skin cancer	0.000339	0.000809	CcSEcCtD
Lurasidone—Rash—Docetaxel—skin cancer	0.000337	0.000802	CcSEcCtD
Lurasidone—Dermatitis—Docetaxel—skin cancer	0.000336	0.000802	CcSEcCtD
Lurasidone—Nausea—Docetaxel—skin cancer	0.000317	0.000756	CcSEcCtD
